Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
PLXND1 Biologics Sequence Review Report 2026: Plexin-D1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLXND1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PLXNC1 Biologics Sequence Review Report 2026: Plexin-C1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLXNC1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PLXNB3 Biologics Sequence Review Report 2026: Plexin-B3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLXNB3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PLXNB2 Biologics Sequence Review Report 2026: Plexin-B2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLXNB2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PLXNA4 Biologics Sequence Review Report 2026: Plexin-A4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLXNA4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PLXNA3 Biologics Sequence Review Report 2026: Plexin-A3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLXNA3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PLXNA2 Biologics Sequence Review Report 2026: Plexin-A2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLXNA2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PLXNA1 Biologics Sequence Review Report 2026: Plexin-A1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLXNA1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PECAM1 Biologics Sequence Review Report 2026: Platelet endothelial cell adhesion molecule Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PECAM1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
P2RY14 Biologics Sequence Review Report 2026: P2Y purinoceptor 14 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RY14 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
P2RY13 Biologics Sequence Review Report 2026: P2Y purinoceptor 13 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RY13 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
P2RY12 Biologics Sequence Review Report 2026: P2Y purinoceptor 12 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of P2RY12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
229
230
231
232
233
>>
2260
>